The ranking of the combination of vemurafenib and cobimetinib (SUCRA: 0.66) is superior to encorafenib in combination with binimetinib (SUCRA: 0.39) and combination of vemurafenib and cobimetinib (SUCRA: 0.18).<h4>Conclusions</h4>We identified the lowest AE risk treatment options for BRAF V600-mutant melanoma patients. This evidence concerns the gene BRAF and melanoma.